The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | PEGASUS: pegcetacoplan for PNH
Peter Hillmen
• 17 Jun 2020
Peter Hillmen, MBChB, FRCP, FRCPath, PhD, of the University of Leeds, Leeds, UK, discusses a Phase III study (NCT03500549) evaluating the efficacy and safety of pegcetacoplan, a complement 3 inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
